Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
INNOVATE Corp ( (VATE) ) just unveiled an update.
On February 10, 2026, INNOVATE Corp. reported that MediBeacon’s peer-reviewed article on its transdermal glomerular filtration rate (tGFR) technology was named one of five 2025 Editors’ Choice articles by the Journal of the American Society of Nephrology, after having been featured on the journal’s August 2025 cover. The TGFR System, which uses the Lumitrace injection, a reusable sensor and a monitor to measure kidney function at the point of care, is now being commercially deployed in centers of excellence, initially targeting heart failure monitoring, transplant evaluation and oncology drug dosing, potentially positioning MediBeacon’s technology as a new standard of care and enhancing INNOVATE’s profile in the life sciences sector.
MediBeacon’s point-of-care tGFR approach aims to address the well-known limitations of estimated and traditional measured GFR methodologies, which are often impractical in routine clinical settings. By collaborating with leading hospitals globally and leveraging validated clinical data around the Lumitrace tracer, MediBeacon is seeking to drive early adoption of its TGFR System, which could influence future kidney care practices and underscore the strategic value of INNOVATE’s life sciences investments.
The most recent analyst rating on (VATE) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on INNOVATE Corp stock, see the VATE Stock Forecast page.
Spark’s Take on VATE Stock
According to Spark, TipRanks’ AI Analyst, VATE is a Neutral.
The score is held back primarily by weak financial quality (loss-making profile and balance-sheet stress with negative equity), despite improving cash flow and revenue growth. Technical momentum is supportive (price above key moving averages with positive MACD), and earnings-call updates show growth/backlog strength but also meaningful margin pressure and elevated debt.
To see Spark’s full report on VATE stock, click here.
More about INNOVATE Corp
INNOVATE Corp. is a diversified holding company with a portfolio of assets across infrastructure, life sciences and spectrum, employing about 3,100 people through its subsidiaries. One of its key life sciences interests is a 44.7% stake in MediBeacon Inc., a St. Louis-based medical technology company focused on fluorescent tracer agents and transdermal detection for organ function measurement, supported by a broad global patent estate.
Average Trading Volume: 24,152
Technical Sentiment Signal: Sell
Current Market Cap: $72.51M
For detailed information about VATE stock, go to TipRanks’ Stock Analysis page.